title: The identification of three novel biomarkers of major adverse kidney events.
abstract: OBJECTIVE
  To describe the prognostic value of three novel biomarkers for acute adverse kidney events compared with routine biological markers.
  
  
  METHODS
  We used high-end MS to quantify biomarkers predictive of acute kidney injury (AKI) and major adverse kidney events (MAKE) in 100 adult patients after open heart surgery (n = 100).
  
  
  RESULTS
  Early postoperatively measured LG3 (a C-terminal fragment of perlecan), LTBP2 (latent transforming growth factor binding protein-2), Cathepsin L as well as two other renal biomarkers (NGAL, Cystatin C) had greater predictive value for AKI (n = 23) and MAKE (n = 24) compared with creatinine, urea and urine output.
  
  
  CONCLUSIONS
  LG3, LTBP2 and Cathepsin L deserve further exploration as biomarkers for the early identification of patients at risk of MAKE.
authors.affiliation: Department of Nephrology & Hypertension, Diabetes & Endocrinology Otto-von-Guericke University, Magdeburg, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Haase
authors.forename: Rinaldo
authors.initials: R
authors.lastname: Bellomo
authors.forename: Christian
authors.initials: C
authors.lastname: Albert
authors.forename: Gregoire
authors.initials: G
authors.lastname: Vanpoucke
authors.forename: Griet
authors.initials: G
authors.lastname: Thomas
authors.forename: Wouter
authors.initials: W
authors.lastname: Laroy
authors.forename: Katleen
authors.initials: K
authors.lastname: Verleysen
authors.forename: Siegfried
authors.initials: S
authors.lastname: Kropf
authors.forename: Hermann
authors.initials: H
authors.lastname: Kuppe
authors.forename: Roland
authors.initials: R
authors.lastname: Hetzer
authors.forename: Anja
authors.initials: A
authors.lastname: Haase-Fielitz
mesh_terms: D058186:Acute Kidney Injury / Q000097:blood / Q000175:diagnosis* / Q000652:urine; D000209:Acute-Phase Proteins / Q000652:urine; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood / Q000652:urine; D056668:Cathepsin L / Q000097:blood / Q000652:urine; D055316:Cystatin C / Q000097:blood* / Q000652:urine*; D005260:Female; D019812:Heparan Sulfate Proteoglycans / Q000097:blood* / Q000652:urine*; D006801:Humans; D053779:Latent TGF-beta Binding Proteins / Q000097:blood* / Q000652:urine*; D000071068:Lipocalin-2; D054834:Lipocalins / Q000097:blood / Q000652:urine; D008297:Male; D011518:Proto-Oncogene Proteins / Q000097:blood / Q000652:urine
chemical_list: D000209:Acute-Phase Proteins; D015415:Biomarkers; D055316:Cystatin C; D019812:Heparan Sulfate Proteoglycans; C489506:LCN2 protein, human; C509035:LTBP2 protein, human; D053779:Latent TGF-beta Binding Proteins; D000071068:Lipocalin-2; D054834:Lipocalins; D011518:Proto-Oncogene Proteins; C071927:perlecan; D056668:Cathepsin L
keywords: C-terminal fragment of perlecan; LG3; LTBP2; MAKE; NGAL; cathepsin L; creatinine; cystatin C; latent transforming growth factor binding protein-2; major adverse kidney event; neutrophil gelatinase-associated lipocalin; urea; urine output